<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26890" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Penicillamine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mejias</surname>
            <given-names>Stephanie G.</given-names>
          </name>
          <aff>Retired- UNIBE University- Alumni</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ramphul</surname>
            <given-names>Kamleshun</given-names>
          </name>
          <aff>Shanghai Jiao Tong University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephanie Mejias declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kamleshun Ramphul declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>27</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26890.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Penicillamine has FDA approval as a treatment for Wilson disease and cystinuria. It is used as an off-label treatment option for lead poisoning in children. It is considered a conventional disease-modifying antirheumatic drug (DMARD). This activity presents penicillamine's indications, contraindications, and side effects and highlights the interprofessional team's role in managing patients with Wilson disease and lead poisoning.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of penicillamine.</p></list-item><list-item><p>Describe the adverse effects of penicillamine.</p></list-item><list-item><p>Summarize the contraindications of penicillamine.</p></list-item><list-item><p>Outline interprofessional team strategies for improving care coordination and communication to advance the treatment of lead poisoning with penicillamine and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26890&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26890">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26890.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Penicillamine has FDA approval as a treatment in adults for Wilson disease and cystinuria, and severe rheumatoid arthritis that has failed to respond to conventional therapies.<xref ref-type="bibr" rid="article-26890.r1">[1]</xref><xref ref-type="bibr" rid="article-26890.r2">[2]</xref>&#x000a0;It is considered a conventional disease-modifying antirheumatic drug (DMARD). In pediatric patients, it is used to treat cystinuria and off-label to treat Wilson disease.<xref ref-type="bibr" rid="article-26890.r3">[3]</xref><xref ref-type="bibr" rid="article-26890.r4">[4]</xref>&#x000a0;As a chelating agent, it&#x000a0;has sometimes been used to treat other heavy metal toxicities.<xref ref-type="bibr" rid="article-26890.r5">[5]</xref><xref ref-type="bibr" rid="article-26890.r6">[6]</xref><xref ref-type="bibr" rid="article-26890.r7">[7]</xref></p>
      </sec>
      <sec id="article-26890.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Penicillamine can chelate heavy metals such as copper, lead, and mercury and form a soluble complex that is renally excreted in the urine. It&#x000a0;also&#x000a0;can combine and form disulfide bonds with cysteine&#x000a0;resulting in a more soluble compound that facilitates the excretion in urine; this also helps prevent the formation of cystine calculi.&#x000a0;</p>
        <p>In rheumatoid arthritis, it can depress T cell activity, although its precise mechanism of action remains unknown.</p>
        <p>It has a plasma peak time of 1 to 3 hours and a&#x000a0;peak plasma concentration of 1 to 2 mg/L for the 250 mg dose. The drug's half-life is 4 to 6 days. More than 80% is protein-bound, and it is excreted in the urine.<xref ref-type="bibr" rid="article-26890.r8">[8]</xref></p>
      </sec>
      <sec id="article-26890.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Penicillamine is available in 250 mg tablets and 125 mg&#x000a0;and 250 mg&#x000a0;capsules.</p>
        <p>
<bold>Wilson Disease</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Adult&#x000a0;dosing: 750 to 1500 mg/day divided three or four times daily.&#x000a0;The dose that gives an initial 24-hour urinary copper excretion of more than 2 mg/day should be kept constant for three months; dose adjustments are made on the 24-hour urinary copper excretion and free serum copper levels. The maintenance dose should give&#x000a0;a&#x000a0;free copper serum level of less than 10 mcg/dL.</p>
          </list-item>
          <list-item>
            <p>Pediatric dosing: The recommended off-label dosing for pediatric cases of Wilson disease is 20 mg/kg/day divided into 2 to 3 doses. The maximum dose is 1000 mg per day. As with adults,&#x000a0;dose adjustments are made on the 24-hour urinary copper excretion and free serum copper levels.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Cystinuria</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Adult&#x000a0;dosing: 500 mg by mouth daily; start with 250 mg daily, increase the dose gradually. The maximum dose is 4000 mg daily.</p>
          </list-item>
          <list-item>
            <p>Pediatric dosing:&#x000a0;30 mg/kg/day by mouth divided&#x000a0;into two or three doses daily. The maximum dose is 4000 mg per day. The initial dose is usually 250 mg/day, gradually titrated upward to reduce the risk of adverse effects. The&#x000a0;goal is to limit the excretion rate of cysteine to 100 to 200 mg/day.</p>
          </list-item>
        </list>
        <p>
<bold>Rheumatoid Arthritis (RA)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Adult dosing:&#x000a0;The typical maintenance dose is 500&#x000a0;to 750 mg daily in divided dosages; some patients may require up to 1500 mg daily to obtain a therapeutic benefit. Start with&#x000a0;125&#x000a0;to 250 mg daily for the initial four weeks, increasing&#x000a0;by the same amount every 4 to 12 weeks until achieving remission. The minimum maintenance dose for symptomatic suppression should be used, and therapy should be discontinued if the patient shows insufficient benefit within&#x000a0;12 months.<xref ref-type="bibr" rid="article-26890.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Pediatric dosing:&#x000a0;Typical maintenance dosing is 15 to 20mg/kg/day.&#x000a0;Start at a lower dose of 2.5 to 5mg/kg/day and increase every four weeks over three to six months.</p>
          </list-item>
        </list>
        <p>&#x000a0;<bold>Lead Poisoning</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>It can be a treatment for lead poisoning if no other preferred chelating agents are available. For&#x000a0;adults, the daily oral dose&#x000a0;is between 1000&#x000a0;and 1500 mg daily in divided doses until the urinary lead&#x000a0;stabilizes at less than 0.5 mg/day.<xref ref-type="bibr" rid="article-26890.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>Penicillamine should be&#x000a0;administered on an empty stomach, at least 1 hour before meals or 2 hours after meals. Some protocols recommend taking the drug at least 2 hours before meals&#x000a0;in cases of lead poisoning. It is also advisable to take the medication at least 1 hour apart from other medications or zinc-containing products and if the patient is consuming milk or antacids. It is a strong recommendation to supplement the patient with pyridoxine. In patients with Wilson disease, 25 to 50 mg/day of pyridoxine is advised. A multivitamin regimen without copper can also be an option. In patients with rheumatoid arthritis or cystinuria, the recommendation is to take 25 mg of pyridoxine per day. The last dose of the day should be taken at least 3 hours after dinner. It is recommended to administer penicillamine with pyridoxine dosed at 25 mg per day for both adults and children, especially in patients with nutritional deficiencies.<xref ref-type="bibr" rid="article-26890.r10">[10]</xref></p>
        <p>Dosing should be decreased if the patient is having surgery and maintained at the reduced dose until wound healing is complete.</p>
        <p>Renal and hepatic dosing: For rheumatoid arthritis patients, penicillamine is contraindicated in renal impairment. For other indications in patients with renal impairment, if creatinine clearance is greater than 50, caution is advised, and if creatinine clearance is below 50, penicillamine use should be avoided. The drug should also not be used in cases of peritoneal or hemodialysis.&#x000a0;Hepatic dosing&#x000a0;is undefined.</p>
      </sec>
      <sec id="article-26890.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Most Common Adverse Effects&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diarrhea</p>
          </list-item>
          <list-item>
            <p>Dysgeusia</p>
          </list-item>
        </list>
        <p>
<bold>Less Common Adverse Effects&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Skin rash</p>
          </list-item>
          <list-item>
            <p>Proteinuria</p>
          </list-item>
          <list-item>
            <p>Thrombocytopenia</p>
          </list-item>
          <list-item>
            <p>Leukopenia</p>
          </list-item>
        </list>
        <p>
<bold>Rare Adverse Effects</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Local thrombophlebitis, vasculitis</p>
          </list-item>
          <list-item>
            <p>Anxiety, agitation, dystonia, Guillain-Barre syndrome, myasthenia (including extraocular muscles), myasthenia gravis, neuropathy, psychiatric disturbance</p>
          </list-item>
          <list-item>
            <p>Agranulocytosis, aplastic anemia, pure red cell aplasia, sideroblastic anemia, positive ANA titer, thrombotic thrombocytopenic purpura</p>
          </list-item>
          <list-item>
            <p>Increased serum alkaline phosphatase, hepatic failure, intrahepatic cholestasis</p>
          </list-item>
          <list-item>
            <p>Lupus-like syndrome</p>
          </list-item>
          <list-item>
            <p>Diplopia, optic neuritis, visual disturbance</p>
          </list-item>
          <list-item>
            <p>Tinnitus, renal failure, asthma, interstitial pneumonitis, pulmonary fibrosis</p>
          </list-item>
          <list-item>
            <p>Breast disease (mammary hyperplasia), Goodpasture syndrome, hematuria, nephrotic syndrome</p>
          </list-item>
          <list-item>
            <p>Dermatomyositis, polymyositis<xref ref-type="bibr" rid="article-26890.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Polyarthralgia (migratory, often with objective synovitis)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26890.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Penicillamine is contraindicated in the following conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients with a previous history of penicillamine-related aplastic anemia</p>
          </list-item>
          <list-item>
            <p>Penicillin allergy, discontinue if an immune reaction</p>
          </list-item>
          <list-item>
            <p>Renal insufficiency and rheumatoid arthritis</p>
          </list-item>
          <list-item>
            <p>Pregnancy risk factor D (It has correlations with multiple congenital disabilities such as congenital cutix laxa)</p>
          </list-item>
          <list-item>
            <p>Concurrency with antimalarials, immunosuppressants</p>
          </list-item>
        </list>
        <p>Pregnancy: Penicillamine is contraindicated in pregnancy for rheumatoid arthritis. Use during pregnancy should be avoided for cystinuria. For Wilson disease, the clinician must weigh the risk vs. benefits and limit dosing to 750 mg daily in capsule form and 1,000 mg daily in tablet form. If the patient is to have a cesarean delivery, dosing should be limited to 250 mg daily for the six weeks prior to the delivery procedure.<xref ref-type="bibr" rid="article-26890.r12">[12]</xref></p>
        <p>Breastfeeding: The presence of the drug in breast milk is unknown and not documented, but avoidance is recommended based on conflicting human data.<xref ref-type="bibr" rid="article-26890.r13">[13]</xref> The manufacturer advises against breastfeeding.</p>
      </sec>
      <sec id="article-26890.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Given the adverse effects, recommendations are to monitor for the following:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Allergic Reactions: </bold>33% of patients can present with an allergic reaction to the drug. It often presents with a rash that heals on stopping the drug. The patient should stop the medication if the patient presents with fever, arthralgia, and lymphadenopathy.<xref ref-type="bibr" rid="article-26890.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Pulmonary:</bold> Patients presenting with dyspnea should undergo a pulmonary function test. It&#x000a0;also&#x000a0;is associated with obliterative bronchiolitis.<xref ref-type="bibr" rid="article-26890.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Dermatologic:</bold> Patients can present with a drug-induced lupus-like rash and other dermatologic changes. It&#x000a0;also&#x000a0;has been associated with pemphigus<xref ref-type="bibr" rid="article-26890.r16">[16]</xref>, and the recommendations to stop the drug and start treatment on high-dose corticosteroids.</p>
          </list-item>
          <list-item>
            <p><bold>Gastrointestinal:</bold> Patients can present with multiple gastrointestinal side effects such as taste alteration, oral ulceration, and gingivostomatitis. These may require discontinuation of the drug based on severity.</p>
          </list-item>
          <list-item>
            <p><bold>Renal:</bold> Penicillamine has shown correlations with multiple renal side effects such as Goodpasture syndrome, proteinuria, and hematuria. Proper renal function tests should be done in patients experiencing such complaints or having risk factors.<xref ref-type="bibr" rid="article-26890.r17">[17]</xref><xref ref-type="bibr" rid="article-26890.r18">[18]</xref><xref ref-type="bibr" rid="article-26890.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Hepatic: </bold>Periodic liver function tests should also be done as penicillamine correlates with intrahepatic cholestasis, hepatitis, and increased alanine aminotransferase and aspartate aminotransferase levels.</p>
          </list-item>
        </list>
        <p>The drug should be used with caution in the elderly as they are more at risk of developing a skin rash and gastrointestinal side effects.</p>
        <p>Penicillamine also interacts with the following drugs:</p>
        <p>
<bold>Major Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Aluminum hydroxide</p>
          </list-item>
          <list-item>
            <p>Calcium carbonate</p>
          </list-item>
          <list-item>
            <p>Carbonyl iron</p>
          </list-item>
          <list-item>
            <p>Copper</p>
          </list-item>
          <list-item>
            <p>Ferrous fumarate</p>
          </list-item>
          <list-item>
            <p>Digoxin</p>
          </list-item>
          <list-item>
            <p>Ferrous gluconate</p>
          </list-item>
          <list-item>
            <p>Ferrous sulfate</p>
          </list-item>
          <list-item>
            <p>Iron dextran</p>
          </list-item>
          <list-item>
            <p>Magnesium citrate</p>
          </list-item>
          <list-item>
            <p>Magnesium hydroxide</p>
          </list-item>
          <list-item>
            <p>Magnesium oxide</p>
          </list-item>
          <list-item>
            <p>Magnesium sulfate</p>
          </list-item>
          <list-item>
            <p>Pyridoxine</p>
          </list-item>
          <list-item>
            <p>Peramivir</p>
          </list-item>
          <list-item>
            <p>Polysaccharide iron</p>
          </list-item>
          <list-item>
            <p>Promazine</p>
          </list-item>
          <list-item>
            <p>Sodium bicarbonate</p>
          </list-item>
          <list-item>
            <p>Sodium citrate/citric acid</p>
          </list-item>
          <list-item>
            <p>Tenofovir</p>
          </list-item>
        </list>
        <p>The following drugs decrease the levels of penicillamine:</p>
        <list list-type="bullet">
          <list-item>
            <p>Aluminum hydroxide</p>
          </list-item>
          <list-item>
            <p>Calcium carbonate&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Carbonyl iron copper</p>
          </list-item>
          <list-item>
            <p>Ferrous fumarate</p>
          </list-item>
          <list-item>
            <p>Iron dextran complex</p>
          </list-item>
          <list-item>
            <p>Magnesium chloride</p>
          </list-item>
          <list-item>
            <p>Magnesium citrate</p>
          </list-item>
          <list-item>
            <p>Magnesium hydroxide</p>
          </list-item>
          <list-item>
            <p>Magnesium oxide</p>
          </list-item>
          <list-item>
            <p>Sodium bicarbonate</p>
          </list-item>
          <list-item>
            <p>Digoxin</p>
          </list-item>
        </list>
        <p>The following drugs increase levels of penicillamine:</p>
        <list list-type="bullet">
          <list-item>
            <p>Peramivir</p>
          </list-item>
          <list-item>
            <p>Promazine</p>
          </list-item>
        </list>
        <p>During the first month of therapy, it is advisable to check the blood cell levels with a complete blood count, platelet count, and urinalysis and properly monitor for any changes in the skin, lymph nodes, and body temperature twice weekly. From the second month until the fifth month, the laboratory and physical findings should be checked every two weeks, and from the sixth month onwards, it should receive testing every month.<xref ref-type="bibr" rid="article-26890.r20">[20]</xref></p>
      </sec>
      <sec id="article-26890.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Clinicians need to be familiar with the toxicity of penicillamine, understand special dosing considerations, and never use the drug casually. Patients should be under close clinical supervision and understand to report any symptoms suggesting toxicity, such as fever, bleeding, bruising, and chills. Gold sodium thiomalate can cause the toxicity of penicillamine and should be avoided.<xref ref-type="bibr" rid="article-26890.r21">[21]</xref><xref ref-type="bibr" rid="article-26890.r22">[22]</xref></p>
      </sec>
      <sec id="article-26890.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Members of&#x000a0;the interprofessional healthcare team, including clinicians (MDs, DOs, NPs, PAs), who prescribe penicillamine, should be familiar with its pharmacology. Because the agent can bind many drugs and minerals, regular monitoring of the patient is necessary. Nursing staff can counsel the patient on the drug and assist with monitoring. The pharmacist should educate the patient not to take the other medications at the same time as penicillamine, watch for drug-drug interactions, and verify dosing is appropriate for the condition being treated and the patient's age and health status. All interprofessional team members need to participate in close monitoring of therapy to prevent adverse events and therapeutic failure. Finally, before prescribing this agent, always ask if the patient has any allergies; nearly 30% of patients develop some type of allergic reaction to penicillamine.<xref ref-type="bibr" rid="article-26890.r23">[23]</xref><xref ref-type="bibr" rid="article-26890.r24">[24]</xref>&#x000a0;This interprofessional team dynamic will optimize therapeutic results while minimizing adverse events with penicillamine therapy, improving patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-26890.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26890&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26890">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26890/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26890">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26890.s11">
        <title>References</title>
        <ref id="article-26890.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <article-title>Treatment guidelines for lead exposure in children. American Academy of Pediatrics Committee on Drugs.</article-title>
            <source>Pediatrics</source>
            <year>1995</year>
            <month>Jul</month>
            <volume>96</volume>
            <issue>1 Pt 1</issue>
            <fpage>155</fpage>
            <page-range>155-60</page-range>
            <pub-id pub-id-type="pmid">7596706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hedera</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Clinical management of Wilson disease.</article-title>
            <source>Ann Transl Med</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>Suppl 2</issue>
            <fpage>S66</fpage>
            <pub-id pub-id-type="pmid">31179303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Socha</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Czlonkowska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Janczyk</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Litwin</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Wilson's disease- management and long term outcomes.</article-title>
            <source>Best Pract Res Clin Gastroenterol</source>
            <year>2022</year>
            <season>Feb-Mar</season>
            <volume>56-57</volume>
            <fpage>101768</fpage>
            <pub-id pub-id-type="pmid">35331405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Das</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Sen Sarma</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Srivastava</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yachha</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Poddar</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Effect of chelation therapy in pediatric Wilson's disease: Liver and endoscopic outcome.</article-title>
            <source>J Hepatobiliary Pancreat Sci</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>336</fpage>
            <page-range>336-345</page-range>
            <pub-id pub-id-type="pmid">32745371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seetharaman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sarma</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Chelation therapy in liver diseases of childhood: Current status and response.</article-title>
            <source>World J Hepatol</source>
            <year>2021</year>
            <month>Nov</month>
            <day>27</day>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>1552</fpage>
            <page-range>1552-1567</page-range>
            <pub-id pub-id-type="pmid">34904029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <chapter-title>Chelating Agents</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2017</year>
            <month>1</month>
            <day>23</day>
            <pub-id pub-id-type="pmid">31643849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vahabzadeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Balali-Mood</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Banagozar Mohammadi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moshiri</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and expenses of succimer vs. d-penicillamine plus garlic in the treatment of lead poisoning: a retrospective cross-sectional study.</article-title>
            <source>Daru</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>477</fpage>
            <page-range>477-481</page-range>
            <pub-id pub-id-type="pmid">34313939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perrett</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The metabolism and pharmacology of D-penicillamine in man.</article-title>
            <source>J Rheumatol Suppl</source>
            <year>1981</year>
            <season>Jan-Feb</season>
            <volume>7</volume>
            <fpage>41</fpage>
            <page-range>41-50</page-range>
            <pub-id pub-id-type="pmid">7014876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Negrei</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bojinca</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Balanescu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bojinca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baconi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Spandidos</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Tsatsakis</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Stan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Management of rheumatoid arthritis: Impact and risks of various therapeutic approaches.</article-title>
            <source>Exp Ther Med</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>1177</fpage>
            <page-range>1177-1183</page-range>
            <pub-id pub-id-type="pmid">27073419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lheureux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Penaloza</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gris</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pyridoxine in clinical toxicology: a review.</article-title>
            <source>Eur J Emerg Med</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>78</fpage>
            <page-range>78-85</page-range>
            <pub-id pub-id-type="pmid">15756083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levy</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alter</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Penicillamine: review and cutaneous manifestations.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1983</year>
            <month>Apr</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>548</fpage>
            <page-range>548-58</page-range>
            <pub-id pub-id-type="pmid">6222087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mussi</surname>
                <given-names>MCL</given-names>
              </name>
              <name>
                <surname>Nardelli</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Abreu</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Os&#x000f3;rio</surname>
                <given-names>FMF</given-names>
              </name>
              <name>
                <surname>Can&#x000e7;ado</surname>
                <given-names>GGL</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>TCA</given-names>
              </name>
              <name>
                <surname>Faria</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Couto</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Pregnancy Outcomes in Wilson's Disease Women: Single-Center Case Series.</article-title>
            <source>Fetal Pediatr Pathol</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>741</fpage>
            <page-range>741-748</page-range>
            <pub-id pub-id-type="pmid">34350816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <chapter-title>Penicillamine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hsu</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Ni</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Steroids used to desensitize penicillamine allergy in Wilson disease.</article-title>
            <source>Acta Paediatr Taiwan</source>
            <year>1999</year>
            <season>Nov-Dec</season>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>448</fpage>
            <page-range>448-50</page-range>
            <pub-id pub-id-type="pmid">10927964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bruguera-&#x000c0;vila</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Mart&#x000ed;nez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Garcia-Oliv&#x000e9;</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-Ochoa</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Barenys</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ruiz-Manzano</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Obliterating bronchiolitis in a patient treated with (D)-penicillamine.</article-title>
            <source>Arch Bronconeumol</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>49</volume>
            <issue>9</issue>
            <fpage>411</fpage>
            <page-range>411-2</page-range>
            <pub-id pub-id-type="pmid">23582262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khashoggi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Machet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Perrinaud</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brive</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Machet</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Maruani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vaillant</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>[D-penicillamine-induced pemphigus: changes in anti-32-2B immunostaining patterns].</article-title>
            <source>Ann Dermatol Venereol</source>
            <year>2013</year>
            <season>Aug-Sep</season>
            <volume>140</volume>
            <issue>8-9</issue>
            <fpage>531</fpage>
            <page-range>531-4</page-range>
            <pub-id pub-id-type="pmid">24034638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bienaim&#x000e9;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Clerbaux</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Plaisier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mougenot</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ronco</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rougier</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>D-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>50</volume>
            <issue>5</issue>
            <fpage>821</fpage>
            <page-range>821-5</page-range>
            <pub-id pub-id-type="pmid">17954295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nanke</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Akama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Terai</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kamatani</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Rapidly progressive glomerulonephritis with D-penicillamine.</article-title>
            <source>Am J Med Sci</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>320</volume>
            <issue>6</issue>
            <fpage>398</fpage>
            <page-range>398-402</page-range>
            <pub-id pub-id-type="pmid">11149553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karpinski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jothy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Radoux</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baran</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>D-penicillamine-induced crescentic glomerulonephritis and antimyeloperoxidase antibodies in a patient with scleroderma. Case report and review of the literature.</article-title>
            <source>Am J Nephrol</source>
            <year>1997</year>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>528</fpage>
            <page-range>528-32</page-range>
            <pub-id pub-id-type="pmid">9426850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Galindo</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>20</volume>
            <issue>11</issue>
            <fpage>1443</fpage>
            <page-range>1443-1450</page-range>
            <pub-id pub-id-type="pmid">34259127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sehgal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fazal</surname>
                <given-names>ZZ</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sheeran</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Progressive dermopathy akin to pseudoxanthoma elasticum after D-penicillamine use in a patient with cystinuria.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2022</year>
            <month>Oct</month>
            <day>06</day>
            <volume>61</volume>
            <issue>10</issue>
            <fpage>e324</fpage>
            <pub-id pub-id-type="pmid">35212711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pitman</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Huynh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bjarnason</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>An</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Malkhasyan</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>A case report and focused literature review of d-penicillamine and severe neutropenia: A serious toxicity from a seldom-used drug.</article-title>
            <source>Clin Case Rep</source>
            <year>2019</year>
            <month>May</month>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>990</fpage>
            <page-range>990-994</page-range>
            <pub-id pub-id-type="pmid">31110732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vajdi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Paravar</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Penicillamine-associated cutis laxa and milia en plaque - case report and review of cutaneous changes associated with penicillamine.</article-title>
            <source>Dermatol Online J</source>
            <year>2016</year>
            <month>May</month>
            <day>15</day>
            <volume>22</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">27617526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26890.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>SQ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>XF</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Clinical efficacy and safety of chelation treatment with typical penicillamine in cross combination with DMPS repeatedly for Wilson's disease.</article-title>
            <source>J Huazhong Univ Sci Technolog Med Sci</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>743</fpage>
            <page-range>743-747</page-range>
            <pub-id pub-id-type="pmid">24142730</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
